Source: International Congress 2019 – Idiopathic pulmonary fibrosis and surroundings
Disease area: Interstitial lung diseases



Rating:

Share or cite this content

Citations should be made in the following way:
J. Behr (Munich, Germany), H. Wirtz (Leipzig, Germany), D. Pittrow (Dresden, Germany), A. Prasse (Hannover, Germany), D. Koschel (Coswig, Germany), S. Geier (Ingelheim, Germany), J. Klotsche (Berlin, Germany), S. Andreas (Göttingen, Germany), M. Claussen (Grosshansdorf, Germany), C. Grohé (Berlin, Germany), H. Wilkens (Homburg, Germany), L. Hagmeyer (Solingen, Germany), D. Skowasch (Bonn, Germany), J. Meyer (Munich, Germany), J. Kirschner (Bamberg, Germany), S. Gläser (Greifswald, Germany), N. Kahn (Heidelberg, Germany), T. Welte (Hannover, Germany), C. Neurohr (Gerlingen, Germany), M. Schwaiblmair (Augsburg, Germany), M. Held (Würzburg, Germany), T. Bahmer (Grosshansdorf, Germany), T. Oqueka (Hamburg, Germany), M. Frankenberger (Munich, Germany), M. Kreuter (Heidelberg, Germany). Late Breaking Abstract - Survival and course of lung function in patients with idiopathic pulmonary fibrosis with or without antifibrotic treatment: long-term results of the INSIGHTS-IPF registry. 250

Member's Comments

No comment yet.

Related content which might interest you: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis: long-term results of the INSIGHTS-IPF registry Source: Eur Respir J, 56 (2) 1902279; 10.1183/13993003.02279-2019 Year: 2020 Reply: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2100283; 10.1183/13993003.00283-2021 Year: 2021 Late Breaking Abstract - Tiotropium/olodaterol improves pulmonary function in patients with treatment naive COPD Source: International Congress 2019 – COPD clinical trials: inhaled and oral therapies Year: 2019 Comment on: Survival and course of lung function in the presence or absence of antifibrotic treatment in patients with idiopathic pulmonary fibrosis Source: Eur Respir J, 57 (3) 2004645; 10.1183/13993003.04645-2020 Year: 2021 Late Breaking Abstract - Effectiveness and tolerability of pirfenidone (PFD) in patients with idiopathic pulmonary fibrosis (IPF) from a large Italian practice cohort Source: International Congress 2018 – Progress in basic and translational research on idiopathic interstitial pneumonias Year: 2018 Long-term outcomes of antifibrotic treatments in patients with idiopathic pulmonary fibrosis: Real-world experience Source: Virtual Congress 2020 – Real life in the field of idiopathic pulmonary fibrosis: treatments and registries Year: 2020 Survival in idiopathic pulmonary fibrosis: results of the IFIGENIA follow up study Source: Eur Respir J 2004; 24: Suppl. 48, 254s Year: 2004 Clinical outcomes of patients with idiopathic pulmonary fibrosis in clinical practice: Follow-up results of the INSIGHTS-IPF registry Source: International Congress 2015 – IPF: clinical aspects II Year: 2015 Emerging potential treatments: new hope for idiopathic pulmonary fibrosis patients? Source: Eur Respir Rev 2011; 20: 201-207 Year: 2011 Real-life experience with pirfenidon in idiopathic pulmonary fibrosis: Does early treatment start predict better therapy adherence? Source: International Congress 2015 – IPF: from bench to bedside Year: 2015 Mortality outcomes in patients with idiopathic pulmonary fibrosis treated with antifibrotics: a real world study Source: Virtual Congress 2021 – News in treatment and diagnosis of idiopathic interstitial pneumonia Year: 2021 Symptoms and quality of life in relation to lung function and comorbidities in patients with idiopathic pulmonary fibrosis: INSIGHTS-IPF registry Source: International Congress 2016 – IPF clinical Year: 2016 Long-term survival analysis: Pirfenidone compared to standard care for the treatment of patients with idiopathic pulmonary fibrosis Source: International Congress 2014 – Clinical trials in IPF Year: 2014 Survival benefit of lung transplantation for patients with idiopathic pulmonary fibrosis Source: Eur Respir J 2002; 20: Suppl. 38, 347s Year: 2002 Predictors of response to pirfenidone treatment in patients with idiopathic pulmonary fibrosis (IPF) Source: International Congress 2016 – IPF treatment II Year: 2016 Predicting survival in newly diagnosed idiopathic pulmonary fibrosis: a 3-year prospective study Source: Eur Respir J 2012; 40: 101-109 Year: 2012 Late Breaking Abstract: Tiotropium improves lung function in patients with severe uncontrolled asthma Source: Annual Congress 2010 - Treatment options for asthma Year: 2010 Late Breaking Abstract - Association of lung clearance index with survival in patients with cystic fibrosis Source: International Congress 2019 – Advances in care and monitoring of cystic fibrosis Year: 2019 Long-term treatment with nintedanib in patients with IPF: An update from INPULSIS®-ON Source: International Congress 2016 – IPF treatment II Year: 2016 Real-world antifibrotic treatment persistence and clinical outcomes for patients with idiopathic pulmonary fibrosis Source: Virtual Congress 2021 – Interstitial lung disease around the world Year: 2021